Thomas Lander, MD
started his industrial career with Boehringer Ingelheim in 1987 and was then appointed Medical Director for NovoNordisk, Bristol-Myers Squibb and GlaxoSmithKline Germany and Europe. He joined Merck KGaA (now Merck Serono) in 2003 as Exec VP Global Clinical Development and Chief Medical Officer with a strong focus on the clinical development of Erbitux.
In 2006, Thomas made a move to the biopharmaceutical industry as Managing Director of CureVac GmbH, Tuebingen. He successfully led the early development of two first-in-class mRNA-based tumorvaccines in Europe and the US resulting with CTA approval.
Thomas Lander is board certified in Internal Medicine and specialized as a diabetologist. Besides he has spent several years doing basic research in immunology and clinical immune intervention trials.
He started his own business as an independent consultant in 2009, also serving as a board director to several biotech companies.
Dieter Goette, MD
has a clinical background and also specific expertise in clinical pharmacology. He started his career with Hoechst AG (Business Unit Head Analgesics, Head Corporate Medical Affairs) and later on acted as European Medical Director for Aventis and Sanofi-Aventis.
From 2005 to 2008 he served as Chief Scientific Officer for Novartis Pharma in Nuremberg and from 2008 to 2010 he had global responsibility as Chief Medical Officer at Basilea Pharmaceuticals Ltd., Basel.
His areas of expertise comprise clinical development of drug candidates and medical devices, scientific product positioning, as well as medical affairs and marketing aspects of the health care business. Specific knowledge will be provided for the following indications: antibiotic therapy, cardiovascular diseases, cns and rheumatology.
From 2010 onwards he created his own business as consultant to the biopharmaceutical industry and also to academic and public institutions.